發(fā)布時間：2018-01-26 14:21

  本文關(guān)鍵詞： 宮頸癌 放療 化療 奈達(dá)鉑 紫杉醇 療效　出處：《中華腫瘤防治雜志》2016年S2期 　論文類型：期刊論文

【摘要】：目的研究觀察同步放療聯(lián)合奈達(dá)鉑、紫杉醇在宮頸癌治療中的臨床效果。方法選擇2012-02-2015-02我院收治的48例宮頸癌患,按治療方法分為聯(lián)合組和對照組。聯(lián)合組采用同步放療聯(lián)合奈達(dá)鉑+紫杉醇治療,對照組采用單純同步放療進(jìn)行治療,對比兩組患者治療效果。結(jié)果聯(lián)合組腫瘤緩解總有效率為87.5%,對照組58.33%,數(shù)據(jù)比較差異均具有統(tǒng)計學(xué)意義,P0.05;聯(lián)合組各項不良反應(yīng)發(fā)生率高于對照組,數(shù)據(jù)比較差異不具有統(tǒng)計學(xué)意義,P0.05;隨訪12個月,聯(lián)合組總生存率83.3%、無遠(yuǎn)處轉(zhuǎn)移生存率75.0%、無局部復(fù)發(fā)率79.2%均明顯高于對照組54.2%、45.8%、50%,數(shù)據(jù)比較差異具有統(tǒng)計學(xué)意義,P0.05。結(jié)論同步放療聯(lián)合奈達(dá)鉑+紫杉醇治療可對腫瘤達(dá)到有效緩解,改善腫瘤分期,提高患者生存率,具有較高安全性,治療效果顯著。
[Abstract]:Objective to observe the clinical effect of simultaneous radiotherapy combined with nedatin and paclitaxel in the treatment of cervical cancer. Methods 48 cases of cervical cancer were treated in our hospital from 2012-02-2015-02. According to the treatment method, the combined group was divided into the combined group and the control group. The combined group was treated with simultaneous radiotherapy combined with nedatin paclitaxel, while the control group was treated with simple simultaneous radiotherapy. Results the total effective rate of tumor remission was 87.5 in the combined group and 58.33 in the control group. The incidence of adverse reactions in the combined group was higher than that in the control group, and there was no significant difference in the data between the two groups (P 0.05). After 12 months follow-up, the overall survival rate of the combined group was 83.3%, the survival rate without distant metastasis was 75.0%, and the non-local recurrence rate of 79.2% was significantly higher than that of the control group (54.25.8%). Conclusion simultaneous radiotherapy combined with neidplatin paclitaxel can improve the tumor stage and survival rate. It has high safety and remarkable therapeutic effect.
【作者單位】： 浙江省中醫(yī)院婦科;
【分類號】：R737.33
【正文快照】： 中華腫瘤防治雜志,2016,23(S2):267-268宮頸癌是婦科常見惡性腫瘤,在女性惡性腫瘤發(fā)病率中位居第二,其病情發(fā)展迅速,具有較高的死亡率[1]。其發(fā)病因素包括病毒感染、分娩、性行為、營養(yǎng)不良、衛(wèi)生習(xí)慣差等,其中持續(xù)高危型HPV病毒感染為主要因素,約占致病原因的90%,原位宮頸癌

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 劉平;魏子白;于俊巖;常建蘭;田向陽;張寧寧;李璐璐;張蓉;張瑛;黃然欣;喬鮮麗;郭紅亮;;奈達(dá)鉑或順鉑聯(lián)合紫杉醇同步放化療治療中晚期宮頸癌的臨床療效觀察[J];中華臨床醫(yī)師雜志(電子版);2015年10期

2 龍霞;吳逢波;徐s，

本文編號：1465830